論文・技術情報追加のお知らせ

1. Further optimization of an ADMA Biologic's proprietary manufacturing process to ensure removal of impurities associated with thrombosis risk in IVIG products.

IVIG製剤不純物低減による血栓症リスク削減とFAERS評価。

対象DB：FAERS

2. Disproportionality analysis of adverse event signals associated with seven Alzheimer's drugs: insights from the FAERS database.

FAERSに基づくアルツハイマー病治療薬7種の副作用比較。

対象DB：FAERS

3. Detection of adverse event signals associated with key immunosuppressants for autoimmune hepatitis: insights from the food and drug administration adverse event reporting system database.

自己免疫性肝炎治療用免疫抑制剤の副作用シグナル比較解析。

対象DB：FAERS

4. GLP-1R expression and dermatological diseases: a mendelian randomization and real-world study.

GLP-1受容体発現と皮膚疾患リスクのメンデル無作為化解析。

対象DB：FAERS

5. Angiogenesis inhibitors and the risk of peripheral artery aneurysm and dissection: a cross-database study.

血管新生阻害薬による末梢動脈瘤・解離の自発報告分析。

対象DB：FAERS,JADER

6. Immune checkpoint inhibitor-related myotoxicity in lung cancer: a decade-long real-world pharmacovigilance analysis of the FAERS database.

肺がんにおける免疫チェックポイント阻害薬関連筋毒性の解析。

対象DB：FAERS

7. Time to onset of amiodarone-induced interstitial lung disease is correlated with the percentage body fat: An analysis of data from the FAERS and JADER databases.

アミオダロン誘発性間質性肺疾患の発現時期と体脂肪率の解析。

対象DB：FAERS,JADER

8. Machine learning-driven pharmacovigilance of antidiabetic drugs: comparative reporting patterns and classification of serious adverse events.

機械学習による糖尿病治療薬の副作用比較と重症度分類。

対象DB：FAERS,KAERS

9. Comparative Adverse Event Reporting Patterns of Amoxicillin and Amoxicillin/Clavulanic Acid in FAERS: A 2022-2025 Disproportionality Analysis.

アモキシシリン単剤とクラブラン酸併用の副作用報告比較。

対象DB：FAERS

10. Safety Profile of Chimeric Antigen Receptor T-cell Therapies in Diffuse Large B-cell Lymphoma: An Analysis of Real-World Adverse Event Reporting From the FDA Adverse Event Reporting System.

DLBCLでのCAR-T細胞療法2種のリアルワールド安全性比較。

対象DB：FAERS

11. Safety Monitoring of COVID-19 Vaccines in the Vaccine Adverse Event Reporting System (VAERS): United States, August 22, 2024-July 4, 2025.

VAERSにおける2024-2025年COVID-19ワクチンの安全性監視。

対象DB：FAERS,VAERS

12. Repurposing Nilotinib as a Selective P38beta Inhibitor in Hematopoietic Malignancies: Clinical Evidence and Mechanistic Insights.

ニロチニブのp38β阻害作用同定と造血器腫瘍への適用検討。

対象DB：FAERS

13. Postmarketing reporting patterns of Candida-related events associated with bimekizumab and selective IL-17A inhibitors in psoriasis: a FAERS and JADER pharmacovigilance study.

IL-17阻害薬におけるカンジダ症自発報告のFAERS解析。

対象DB：JADER

14. Evaluation of Adverse Reactions of Roxadustat and Daprodustat: A Pharmacovigilance Study.

ロキサデュスタットとダプロデュスタットの安全性比較。

対象DB：JADER

15. Safety of nirsevimab in children aged 0-24 months: Analysis based on EudraVigilance data (2023-2025).

乳幼児におけるRSV予防抗体ニルセビマブの欧州安全性解析。

対象DB：EudraVigilance

16. A Scalable Predictive Modeling Approach to Duplicate Detection in Pharmacovigilance: Algorithm Development and Validation Study.

副作用自発報告の重複検出に向けた予測モデルの開発。

対象DB：VigiBase

17. Hallucinations associated with bilastine in a teenager: case report and disproportionality analysis in VigiBase((R)).

ビラスチンによる小児での幻覚症例とVigiBase不均衡分析。

対象DB：VigiBase

18. Lithium-related adverse drug reactions in children: A case-control study comparing lithium to second-generation antipsychotics in VigiBase.

小児におけるリチウムの安全性プロファイルと抗精神病薬比較。

対象DB：VigiBase

19. Noninfectious meningitis related to nusinersen: a pharmacovigilance analysis using the WHO database.

WHOデータベースを用いたヌシネルセン関連髄膜炎の解析。

対象DB：VigiBase

20. Association between hospital-level factors and early rehabilitation initiation in patients with acute ischemic stroke: a multilevel analysis using a Japanese administrative database from a rural prefecture.

脳梗塞患者における早期リハビリ開始と病院要因の分析。

対象DB：DPC

21. Clinical and epidemiological characteristics of patients hospitalized for toxocariasis in Japan: A nationwide analysis using the diagnosis procedure combination database.

日本におけるトキソカラ症入院患者の臨床・疫学特徴解析。

対象DB：DPC

22. Maternal Influenza Infection During Pregnancy and Neuropsychiatric Disorders in Offspring.

妊娠中の母体インフルエンザ感染と児の神経精神疾患リスク。

対象DB：JMDC

23. Serum albumin is associated with immune-related hypothyroidism and treatment continuity in non-small cell lung cancer.

非小細胞肺がんにおける血清アルブミンとICI誘発甲状腺障害。

対象DB：JMDC,MDV

24. Hospitalized Infection Risk and Organ-specific Infection Patterns Across Advanced Therapies in Ulcerative Colitis: A Japanese Claims Analysis.

潰瘍性大腸炎高度治療薬における入院感染症リスクの比較。

対象DB：MDV

25. Trends and safety of small bowel endoscopy in Crohn's disease in Japan: a large-scale claims database analysis.

日本におけるクローン病に対する小腸内視鏡動向と安全性評価。

対象DB：MDV

26. Pregnancy complications and risk of cardiometabolic-renal conditions in 1.4 million women in England: longitudinal study.

妊娠合併症と後年の心血管・代謝・腎疾患リスクの縦断的評価。

対象DB：CPRD

27. Trends in long COVID and post-viral fatigue in children in primary care in England.

英国小児のプライマリケアにおけるLong COVID動向の調査。

対象DB：CPRD

28. Frequency and Timing of Specialized Formula Prescriptions for Children Under 2 Years.

2歳未満小児における特殊アレルギー用粉ミルクの処方実態。

対象DB：CPRD

29. Clinical Burden of Disease and Demographics in Older Adults Hospitalized with RSV Infection in England: A Retrospective Cohort Study.

英国におけるRSV感染入院高齢患者の病態負担と人口統計。

対象DB：CPRD

30. Risk of febrile seizure associated with beta-lactam antibiotic use: a case-crossover study with an active comparator.

βラクタム系抗菌薬投与に伴う小児熱性けいれんリスク評価。

対象DB：DeSC

31. Comparison of Insomnia Risk between Spironolactone and Esaxerenone in Individuals with Hypertension.

高血圧患者におけるスピロノラクトン等の不眠リスク比較。

対象DB：DeSC

32. The PREVENT Risk Equations and Cardiovascular Prevention in East Asia.

東アジア人におけるPREVENT心血管リスク予測式の適用評価。

対象DB：DeSC